Oncology Corporate Profile
Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAb® antibody platform. Affimed’s product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13).
|Brand / Product||Class||Area of Study||Phase||Partnership|
|afm-13||bi-specific tetravalent antibody||Hodgkin's Lymphoma||II|
|afm-13 (+ (pembrolizumab)||bi-specific tetravalent antibody||Hodgkin's Lymphoma||I|
|afm-11||bi-specific tetravalent antibody||Non-Hodgkin's Lymphoma (NHL)||I|
View additional information on product candidates here »